Literature DB >> 25421688

Detection of epigenetic aberrations in the development of hepatocellular carcinoma.

Yujing Zhang1.   

Abstract

Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide. Hepatocarcinogenesis is a complex, multistep process. It is now recognized that HCC is a both genetic and epigenetic disease; genetic and epigenetic components cooperate at all stages of hepatocarcinogenesis. Epigenetic changes involve aberrant DNA methylation, posttranslational histone modifications and aberrant expression of microRNAs all of which can affect the expression of oncogenes, tumor suppressor genes and other tumor-related genes and alter the pathways in cancer development. Several risk factors for HCC, including hepatitis B and C virus infections and exposure to the chemical carcinogen aflatoxin B1 have been found to influence epigenetic changes. Their interactions could play an important role in the initiation and progression of HCC. Discovery and detection of biomarkers for epigenetic changes is a promising area for early diagnosis and risk prediction of HCC.

Entities:  

Mesh:

Year:  2015        PMID: 25421688     DOI: 10.1007/978-1-4939-1804-1_37

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

1.  Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis.

Authors:  George N Ioannou; Pamela Green; Elliott Lowy; Elijah J Mun; Kristin Berry
Journal:  PLoS One       Date:  2018-09-27       Impact factor: 3.240

2.  Epigenetic actions of environmental factors and promising drugs for cancer therapy.

Authors:  Zhong-Tian Bai; Bing Bai; Jun Zhu; Cui-Xia Di; Xun Li; Wen-Ce Zhou
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

3.  Analysis of DNA methylation in plasma for monitoring hepatocarcinogenesis.

Authors:  Wenqing Huang; Tong Li; Wenli Yang; Xinjuan Chai; Kefei Chen; Ling Wei; Shuwang Duan; Bo Li; Yang Qin
Journal:  Genet Test Mol Biomarkers       Date:  2015-04-29

Review 4.  Hepatocellular Carcinoma: The Role of MicroRNAs.

Authors:  Sharad Khare; Tripti Khare; Raghu Ramanathan; Jamal A Ibdah
Journal:  Biomolecules       Date:  2022-04-27

5.  Identifying Hepatocellular Carcinoma Driver Genes by Integrative Pathway Crosstalk and Protein Interaction Network.

Authors:  Wenbiao Chen; Jingjing Jiang; Peizhong Peter Wang; Lan Gong; Jianing Chen; Weibo Du; Kefan Bi; Hongyan Diao
Journal:  DNA Cell Biol       Date:  2019-08-29       Impact factor: 3.311

Review 6.  DNA Methylation and Micro-RNAs: The Most Recent and Relevant Biomarkers in the Early Diagnosis of Hepatocellular Carcinoma.

Authors:  Angela Cozma; Adriana Fodor; Romana Vulturar; Adela-Viviana Sitar-Tăut; Olga Hilda Orăşan; Flaviu Mureşan; Cezar Login; Ramona Suharoschi
Journal:  Medicina (Kaunas)       Date:  2019-09-19       Impact factor: 2.430

7.  Bromodomain-containing protein 9 promotes the growth and metastasis of human hepatocellular carcinoma by activating the TUFT1/AKT pathway.

Authors:  Changwei Dou; Liankang Sun; Liang Wang; Jian Cheng; Weiding Wu; Chengwu Zhang; Qiuran Xu; Kangsheng Tu; Jie Liu
Journal:  Cell Death Dis       Date:  2020-09-09       Impact factor: 8.469

8.  Integrative Analysis of DNA Methylation and microRNA Expression Reveals Mechanisms of Racial Heterogeneity in Hepatocellular Carcinoma.

Authors:  Rency S Varghese; Megan E Barefoot; Sidharth Jain; Yifan Chen; Yunxi Zhang; Amber Alley; Alexander H Kroemer; Mahlet G Tadesse; Deepak Kumar; Zaki A Sherif; Habtom W Ressom
Journal:  Front Genet       Date:  2021-09-07       Impact factor: 4.599

Review 9.  Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review.

Authors:  Saleh Daher; Muhammad Massarwa; Ariel A Benson; Tawfik Khoury
Journal:  J Clin Transl Hepatol       Date:  2017-12-17

10.  Classification of early and late stage liver hepatocellular carcinoma patients from their genomics and epigenomics profiles.

Authors:  Harpreet Kaur; Sherry Bhalla; Gajendra P S Raghava
Journal:  PLoS One       Date:  2019-09-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.